Preventing respiratory syncytial virus infections

Paediatrics and Child Health

Volumn 16, Issue 8, 2011, Pages 488-490

  Robinson, Joan L ^a   Finlay, Jane C ^a   Martin, Susanna ^a   McDonald, Jane C ^a   Onyett, Heather ^a  

^a NONE

Author keywords

At risk infants; Palivizumab; Prematurity; Prophylaxis; RSV

Indexed keywords

PALIVIZUMAB;

ASPIRATION PNEUMONIA; ASTHMA; BIRTH; BIRTH WEIGHT; BREAST FEEDING; BRONCHIOLITIS; CANADA; CIGARETTE SMOKING; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOWN SYNDROME; DRUG COST; DRUG EFFICACY; GENDER; GESTATIONAL AGE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; LOW BIRTH WEIGHT; LUNG MALFORMATION; MORTALITY; NONHUMAN; PIERRE ROBIN SYNDROME; PNEUMOVIRUS INFECTION; PREMATURITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SCORING SYSTEM; SMOKING; UPPER RESPIRATORY TRACT OBSTRUCTION; WHEEZING;

EID: 80053926332     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: 10.1093/pch/16.8.487     Document Type: Review

References (41)

1. Tan B; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Palivizumab and respiratory syncytial virus globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 1999;4(7):474-80.
2. Langley JM; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Use of palivizumab in children with congenital heart disease. Paediatr Child Health 2003;8(10):631-3.
3. Sampson L; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Prevention of respiratory syncytial virus infection. Paediatr Child Health 2009;14(8):521-6.
4. Jefferson T, Del Mar C, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 2010;(1):CD006207.
5. Mitchell I, Paes BA, Li A, Lanctôt KL; the CARESS investigators. CARESS: The Canadian Registry of Palivizumab. Pediatr Infect Dis J 2011;30(8):651-5.
6. Zaaijer HL, Vandenbroucke-Grauls CM, Franssen EJ. Optimum dosage regimen of palivizumab? Ther Drug Monit 2002;24(3):444-5. (Pubitemid 34553214)
7. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The Impact-RSV Study Group. Pediatrics 1998;102(3):531-7.
8. Mitchell I, Tough S, Gillis L, Majaesic C. Beyond randomized controlled trials: A "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol 2006;41(12):1167-74. (Pubitemid 44893870)
9. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant heart disease. J Pediatr 2003;143(4):532-40. (Pubitemid 37352516)
10. Medrano López C, Garcia-Guereta L; CIVIC Study Group. Community-acquired respiratory infections in young children with congenital heart diseases in the palivizumab era: The Spanish 4- season civic epidemiologic study. Pediatr Infect Dis J 2010;29(12):1077-82.
11. Robinson KA, Odelola OA, Saldanha I, McKoy N. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. Cochrane Database Syst Rev 2010;(2):CD007743.
12. Giebels K, Marcotte JE, Podoba J, et al. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis. Pediatr Pulmonol. 2008;43(2):169-74. (Pubitemid 351273044)
13. Smart KA, Lanctôt KL, Paes BA. The cost-effectiveness of palivizumab: A systematic review of the evidence. J Med Econ 2010;13(3):453-63.
14. Hampp C, Kauf TL, Saidi AS, Winterstein AG. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications. Arch Pediatr Adolesc Med 2011;165(6):498-505.
15. Robinson JL. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks; a Canadian-based analysis. Curr Med Res Opin 2009;25(7):1631-2; author reply 1632-3.
16. Lanctôt KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: A Canadian-based analysis. Curr Med Res Opin 2008;24(11):3223-37.
17. Poorisrisak P, Halkjaer LB, Thomsen SF, et al. Causal direction between respiratory syncytial virus bronchiolitis and asthma studied in monozygotic twins. Chest 2010;138(2):338-44.
18. Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: A systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 2011;15(5):iii-iv, 1-124.
19. Tam DY, Banerji A, Paes BA, Hui C, Tarride JE, Lactôt KL. The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. J Med Econ 2009;12(4):361-70.
20. Fiqueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al. FLIP-2 Study: Risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27(9):788-93.
21. Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk-scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making 2008;28(4):471-80. (Pubitemid 351989998)
22. Law BJ, Langley JM, Allen U, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23(9):806-14. (Pubitemid 40221021)
23. Paes B, Steele S, Janes M, Pinelli J. Risk-scoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin 2009;25(7):1585-91.
24. Simões EA, Carbonell-Estrany X, Fullarton JR, et al. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res 2008;9:78.
25. Stensballe LG, Fullarton JR, Carbonell-Estrany X, Simões EA. Population based external validation of a European predictive model for respiratory syncytial virus hospitalization of premature infants born 33 to 35 weeks of gestational age. Pediatr Infect Dis J 2010;29(4):374-6.
26. Carbonell-Estrany X, Simões EA, Fullarton JR, Ferdynus C, Gouyon JB; European RSV Risk Factor Study Group. Validation of a model to predict hospitalization due to RSV of infants born at 33-35 weeks' gestation. J Perinat Med 2010;38(4):411-7.
27. Simões EA, Carbonell-Estrany X, Fullarton JR, et al. European risk factors' model to predict hospitalization of premature infants born 33-35 weeks' gestational age with respiratory syncytial virus: Validation with Italian data. J Matern Fetal Neonatal Med 2011;24(1):152-7.
28. American Academy of Pediatrics, Committee on Infectious Diseases. Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009;124(6):1694-701.
29. Krilov LR, Weiner LB, Yogev R, et al. The 2009 COID recommendations for RSV prophylaxis: Issues of efficacy, cost, and evidence-based medicine. Pediatrics 2009;124(6):1682-4.
30. Law B, MacDonald N, Langley J, et al. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent? Paediatr Child Health 1998;3(6):402-4.
31. Palmer L, Hall CB, Katkin JP, et al. Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infants. Curr Med Res Opin 2011;27(2):403-12.
32. Banerji A, Bell A, Mills EL, et al. Lower respiratory tract infections in Inuit infants on Baffin Island. CMAJ 2001;164(13):1847-50. (Pubitemid 32702069)
33. Young M, Kandola K, Mitchell R, Leamon A. Hospital admission rates for lower respiratory tract infections in infants in the Northwest Territories and Kitikmeot region of Nunavut between 2000 and 2004. Paediatr Child Health 2007;12(7):563-6. (Pubitemid 350075600)
34. Banerji A, Lanctôt KL, Paes BA, et al. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants. Pediatr Infect Dis J 2009;28(8):702-6.
35. Banerji A, Young M, Bisson D, et al. Is an ounce of palivizumab worth a pound of cure? [Abstract] Can J Infect Dis Med Microbiol 2010;21:189.
36. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics 2008;121(2):235-43. (Pubitemid 351198444)
37. Bloemers BL, van Furth AM, Weijerman ME, et al. Down syndrome: A novel risk factor for respiratory syncytial virus bronchiolitis - a prospective birth-cohort study. Pediatrics 2007;120 (4):e1076-81. (Pubitemid 47549555)
38. Bloemers BL, van Furth AM, Weijerman ME, et al. High incidence of recurrent wheeze in children with down syndrome with and without previous respiratory syncytial virus lower respiratory tract infection. Pediatr Infect Dis J 2010;29(1):39-42.
39. Megged O, Schlesinger Y. Down syndrome and respiratory syncytial virus infection. Pediatr Infect Dis J 2010;29(7):672-3.
40. GRADE Working Group. Introduction: Grading the quality of evidence and the strength of recommendations. http://www.gradeworkinggroup.org/intro.htm (Accessed June 30, 2011)
41. Adam O, Bonzel L, Kovacevic A, Mayatepek E, Hoehn T, Vogel M. Palivizumab-resistant human respiratory syncytial virus in infancy. Clin Infect Dis 2010;51(2):185-8.